While "The Tan Sheet" eagerly awaits next week's FDA advisory committee meeting to discuss pediatric dosing of acetaminophen, the OTC industry announced last week it plans to voluntarily move to a standardized concentration of acetaminophen in single-ingredient products for all children up to age 12.
But our May 9 issue has plenty of non-acetaminophen stories, too. We've got exclusive coverage of last week's SupplySide East conference and trade show in Secaucus, N.J., where supplement industry stakeholders examined the food safety law's impact on ingredient suppliers and FDA supplement official Brad Williams said agency inspectors are finding "pretty dismal" compliance with good manufacturing practices.
Additionally, with earnings season in full bloom, "The Tan Sheet" looks at Perrigo's streak of record revenues and profits, and Pfizer's gradually unfolding restructuring plans, which may include consumer business divestments.
["The Tan Sheet" will be your source for news and analysis from the May 17-18 FDA advisory committee meeting on acetaminophen, as well as everything else happening in the world of OTC drugs and nutritionals. For information on a risk-free 30-day trial subscription, click here.]
TOP STORIES
OTC Industry Standardizes Pediatric Liquid Acetaminophen Concentration
Over-the-counter drug firms will make single-ingredient liquid acetaminophen pediatric products only in one standard concentration to help prevent dosing errors, their trade association said May 4.
Supplement Ingredient Suppliers Should Prepare For Food HACCP Regs
The exemption Congress gave dietary supplement manufacturers from the hazard analysis and critical control points regulations for food products does not extend to ingredient suppliers, experts say.
Perrigo Rogaine Foam ANDA May Help Extend Record Growth
Perrigo's regulatory green light to market the first OTC generic of Men's Rogaine Foam further extends the pipeline that has kept the firm on a streak of record earnings.